Aging and Declining Testosterone: Past, Present, and Hopes for the Future

• Published in: Journal of andrology Vol. 33; no. 6; pp. 1111 - 1118
• Main Authors: Zirkin, Barry R., Tenover, Joyce Lisa
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Publishing Ltd 01.11.2012; American Society of Andrology
• Subjects: Adult; Aged; Aging - physiology; Animals; Biological and medical sciences; Fundamental and applied biological sciences. Psychology; Gynecology. Andrology. Obstetrics; Hormone Replacement Therapy; Humans; hypogonadism; Hypogonadism - drug therapy; Leydig cells; Leydig Cells - drug effects; Leydig Cells - metabolism; Luteinizing Hormone - blood; Luteinizing Hormone - physiology; Male; Male genital diseases; Mammalian male genital system; Medical sciences; Middle Aged; Rats; Rats, Inbred BN; Testis - drug effects; Testis - physiology; Testosterone - biosynthesis; Testosterone - blood; Testosterone - deficiency; Testosterone - therapeutic use; Vertebrates: reproduction; Testosterone; Reproduction; Androgen; Ageing; Leydig cells; Testicular hormone; Sex steroid hormone; Testicle; Male genital system; Hypogonadism; Genital diseases; Leydig cell
• ISSN: 0196-3635; 1939-4640
• DOI: 10.2164/jandrol.112.017160

: As men age, serum testosterone (T) levels decline, whereas serum luteinizing hormone (LH) levels increase somewhat or remain unchanged. Age‐related reductions in T levels may be associated with alterations in body composition; energy level; muscle strength; physical, sexual, and cognitive functions; and mood. The predominant contributor to the decline in serum T levels is the decreased ability of the aging testes to make T. As in humans, the Brown Norway rat demonstrates age‐related reductions in serum T levels in the setting of unchanged or modestly increased serum LH levels. In this rat model, the ability of aged Leydig cells, the terminally differentiated T‐producing cells of the testis, to produce T in response to LH stimulation is significantly diminished. This review begins with a discussion of what is known of the molecular mechanisms by which T synthesis declines with Leydig cell aging. It concludes with a brief history of T replacement therapy, current guidelines, controversies related to T replacement therapy in older men, and proposed future clinical directions.